The estimated Net Worth of Helen Sabzevari is at least $4.32 Milión dollars as of 5 April 2024. Dr Sabzevari owns over 1,071,429 units of Precigen Inc stock worth over $2,552,490 and over the last 7 years he sold PGEN stock worth over $0. In addition, he makes $1,765,316 as Pres a CEO & Director at Precigen Inc.
Sign up
Dr D PGEN stock SEC Form 4 insiders trading
Dr has made over 23 trades of the Precigen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,071,429 units of PGEN stock worth $1,039,286 on 5 April 2024.
The largest trade he's ever made was exercising 1,071,429 units of Precigen Inc stock on 5 April 2024 worth over $1,039,286. On average, Dr trades about 70,098 units every 32 days since 2018. As of 5 April 2024 he still owns at least 2,631,433 units of Precigen Inc stock.
You can see the complete history of Dr Sabzevari stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Helen Sabzevari MPH, Ph.D. biography
Dr. Helen Sabzevari MPH, Ph.D. is the Pres, CEO & Director at Precigen Inc.
What is the salary of Dr D?
As the Pres a CEO & Director of Precigen Inc, the total compensation of Dr D at Precigen Inc is $1,765,316. There are 1 executives at Precigen Inc getting paid more, with Randal Kirk having the highest compensation of $2,067,620.
How old is Dr D?
Dr D is 59, he's been the Pres a CEO & Director of Precigen Inc since . There are 9 older and 9 younger executives at Precigen Inc. The oldest executive at Precigen Inc is Robert Shapiro, 81, who is the Lead Independent Director.
Insiders trading at Precigen Inc
Over the last 5 years, insiders at Precigen Inc have traded over $44,216,787 worth of Precigen Inc stock and bought 52,689,457 units worth $114,197,137 . The most active insiders traders include Randal J Kirk, Trading S.A. Ares a Helen Sabzevari. On average, Precigen Inc executives and independent directors trade stock every 9 days with the average trade being worth of $358,866. The most recent stock trade was executed by Randal J Kirk on 9 August 2024, trading 23,529,411 units of PGEN stock currently worth $19,999,999.
What does Precigen Inc do?
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
What does Precigen Inc's logo look like?
Complete history of Dr Sabzevari stock trades at Precigen Inc a Kinnate Biopharma
Precigen Inc executives and stock owners
Precigen Inc executives and other stock owners filed with the SEC include:
-
Randal Kirk,
Executive Chairman of the Board -
Dr. Helen Sabzevari MPH, Ph.D.,
Pres, CEO & Director -
Donald Lehr,
Chief Legal Officer -
Rick Sterling,
Chief Financial Officer -
Jeffrey Perez,
Senior Vice President - Intellectual Property Affairs -
Helen Sabzevari,
President, Chief Executive Officer, President - Precigen, Inc. -
Donald P. Lehr,
Chief Legal Officer & Corp. Sec. -
Jeffrey Thomas Perez,
Sr. VP of Intellectual Property Affairs -
Jeffrey Kindler,
Independent Director -
Robert Shapiro,
Lead Independent Director -
Cesar Alvarez,
Independent Director -
James Turley,
Independent Director -
Dean Mitchell,
Independent Director -
Fred Hassan,
Independent Director -
Vinita Gupta,
Independent Director -
Steven Frank,
Independent Director -
Marie Rossi,
VP of Communications -
Steven Harasym,
Head of Investor Relations -
James Vincent Lambert,
Interim Principal Accounting Officer -
Rutul R. Shah,
Head of Operations & Portfolio -
Harry Thomasian Jr.,
Chief Financial Officer -
Dr. Thomas D. Reed,
Founder & Chief Science Officer -
Randal J. Kirk,
Exec. Chairman -
Harry Jr. Thomasian,
Chief Financial Officer -
Nancy H Agee,
Director -
Rutul R Shah,
Chief Operating Officer -
D. Bradford Osborne,
VP, Finance and Accounting -
Trading S.A. Ares,
10% owner -
Phil Tennant,
Chief Commercial Officer